243 related articles for article (PubMed ID: 23154574)
1. Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
[TBL] [Abstract][Full Text] [Related]
2. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.
Keating K; Walko C; Stephenson B; O'Neil BH; Weiss J
J Oncol Pharm Pract; 2014 Dec; 20(6):409-16. PubMed ID: 24243920
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center.
Hansen NL; Chandiramani DV; Morse MA; Wei D; Hedrick NE; Hansen RA
J Oncol Pharm Pract; 2011 Jun; 17(2):125-30. PubMed ID: 20147576
[TBL] [Abstract][Full Text] [Related]
5. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
6. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre.
Shalviri G; Yousefian S; Gholami K
J Clin Pharm Ther; 2012 Aug; 37(4):448-51. PubMed ID: 22122488
[TBL] [Abstract][Full Text] [Related]
7. Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan.
Yamaguchi K; Watanabe T; Satoh T; Ishiguro M; Izawa M; Inoshiri S; Sugihara K; Sakata Y
Jpn J Clin Oncol; 2014 Jun; 44(6):541-6. PubMed ID: 24771864
[TBL] [Abstract][Full Text] [Related]
8. Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test.
Dupont B; Mariotte D; Clarisse B; Galais MP; Bouhier-Leporrier K; Grellard JM; Le Mauff B; Reimund JM; Gervais R
Future Oncol; 2014 Nov; 10(14):2133-40. PubMed ID: 25471028
[TBL] [Abstract][Full Text] [Related]
9. An infusion reaction to cetuximab.
Waxman ES
Oncology (Williston Park); 2011 Apr; 25(4 Suppl Nurse Ed):38-41. PubMed ID: 25391206
[No Abstract] [Full Text] [Related]
10. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.
Muallaoglu S; Disel U; Mertsoylu H; Besen A; Karadeniz C; Taner Sumbul A; Abali H; Ozyilkan O
J BUON; 2013; 18(1):261-7. PubMed ID: 23613414
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-associated infusion reactions: pathology and management.
Patel DD; Goldberg RM
Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
[TBL] [Abstract][Full Text] [Related]
12. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
13. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH
Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
[TBL] [Abstract][Full Text] [Related]
14. [Incidence of infusion reactions induced by cetuximab chemotherapy].
Maeda T; Tatematsu M; Muro K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of adverse events associated with therapeutic monoclonal antibodies in Korea.
Sim DW; Park KH; Park HJ; Son YW; Lee SC; Park JW; Lee JH
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1279-1286. PubMed ID: 27364925
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system.
Chen CJ; Cheng CF; Lin HY; Hung SP; Chen WC; Lin MS
J Clin Pharm Ther; 2012 Dec; 37(6):647-51. PubMed ID: 22646235
[TBL] [Abstract][Full Text] [Related]
18. Serious adverse drug reactions in older adults notified to pharmacovigilance.
Charfi R; El Aïdli S; Zaïem A; Kastalli S; Sraïri S; Daghfous R; Lakhal M
Therapie; 2012; 67(5):465-70. PubMed ID: 23241256
[TBL] [Abstract][Full Text] [Related]
19. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
O'Neil BH; Allen R; Spigel DR; Stinchcombe TE; Moore DT; Berlin JD; Goldberg RM
J Clin Oncol; 2007 Aug; 25(24):3644-8. PubMed ID: 17704414
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Yang W; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]